Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...

British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian ...

(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up ...

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...